

## PerCP/Cyanine5.5 anti-mouse Ly-6G Antibody

<b>Catalog# / Size</b>	127615 / 25 µg 127616 / 100 µg
<b>Clone</b>	1A8
<b>Regulatory Status</b>	RUO
<b>Other Names</b>	Lymphocyte antigen 6 complex, locus G
<b>Isotype</b>	Rat IgG2a, κ
<b>Description</b>	Lymphocyte antigen 6 complex, locus G (Ly-6G), a 21-25 kD GPI-anchored protein, is expressed on the majority of myeloid cells in bone marrow and peripheral granulocytes.

### Product Details

<b>Verified Reactivity</b>	Mouse
<b>Antibody Type</b>	Monoclonal
<b>Host Species</b>	Rat
<b>Immunogen</b>	Ly-6G transfected EL-4J cell line.
<b>Formulation</b>	Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
<b>Preparation</b>	The antibody was purified by affinity chromatography, and conjugated with PerCP/Cyanine5.5 under optimal conditions.
<b>Concentration</b>	0.2 mg/ml
<b>Storage &amp; Handling</b>	The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. <b>Do not freeze.</b>
<b>Application</b>	<a href="#">FC - Quality tested</a>
<b>Recommended Usage</b>	Each lot of this antibody is quality control tested by <a href="#">immunofluorescent staining with flow cytometric analysis</a> . For flow cytometric staining, the suggested use of this reagent is ≤ 0.25 µg per 10 <sup>6</sup> cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.  * PerCP/Cyanine5.5 has a maximum absorption of 482 nm and a maximum emission of 690 nm.
<b>Application Notes</b>	While 1A8 recognizes only Ly-6G, clone RB6-8C5 recognizes both Ly-6G and Ly-6C. Clone RB6-8C5 binds with high affinity to mouse Ly-6G molecules and to a lower extent to Ly-6C <sup>15</sup> . Clone RB6-8C5 impairs the binding of anti-mouse Ly-6G clone 1A8 <sup>15</sup> . However, clone RB6-8C5 is able to stain in the presence of anti-mouse Ly-6C clone HK1.4 <sup>16</sup> .  Additional reported applications (for the relevant formats) include: immunohistochemistry <sup>9</sup> of frozen sections <sup>10</sup> and paraffin-embedded sections <sup>11</sup> , depletion <sup>4, 12-14</sup> , and spatial biology (IBEX) <sup>20,21</sup> . The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for <i>in vivo</i> studies or highly sensitive assays (Cat. No. 127632, 127649, 127650, 127661 and 127662).
<b>Additional Product Notes</b>	BioLegend is in the process of converting the name PerCP/Cy5.5 to PerCP/Cyanine5.5. The dye molecule remains the same, so you should expect the same quality and performance from our PerCP/Cyanine5.5 products. Contact <a href="#">Technical Service</a> if you have any questions.
<b>Application References</b>	<ol style="list-style-type: none"> <li>1. Fleming TJ, <i>et al.</i> 1993. <i>J. Immunol.</i> 151:2399. (FC)</li> <li>2. Daley JM, <i>et al.</i> 2008. <i>J. Leukocyte Biol.</i> 83:1. (FC)</li> <li>3. Dietlin TA, <i>et al.</i> 2007. <i>J. Leukocyte Biol.</i> 81:1205. (FC)</li> <li>4. Daley J, <i>et al.</i> 2007. <i>J. Leukocyte Biol.</i> doi:10.1189. (Deplete) <a href="#">PubMed</a></li> <li>5. Tadagavadi RK, <i>et al.</i> 2010. <i>J. Immunol.</i> 185:4904. <a href="#">PubMed</a></li> <li>6. Sumagin R, <i>et al.</i> 2010. <i>J. Immunol.</i> 185:7057. <a href="#">PubMed</a></li> <li>7. Guiducci C, <i>et al.</i> 2010. <i>J. Exp Med.</i> 207:2931. <a href="#">PubMed</a></li> </ol>
<b>(PubMed link indicates BioLegend citation)</b>	

8. Fujita M, *et al.* 2011. *Cancer Res.* 71:2664. [PubMed](#)
9. Van Leeuwen, *et al.* 2008. *Arterioscler. Thromb. Vasc. Biol.* 28:84. (IHC)
10. Kowanetz M, *et al.* 2010. *P. Natl. Acad. Sci. USA* 107:21248. [supplementary data] (IHC)
11. Esbona K, *et al.* 2016. *Breast Cancer Res.* 18:35. (IHC)
12. Wojtasiak M, *et al.* 2010. *J. Gen. Virol.* 91:2158. (FC, Deplete)
13. Jaeger BN, *et al.* 2012. *J. Exp. Med.* 209:565. (Deplete)
14. Wozniak KL, *et al.* 2012. *BMC Immunol.* 13:65 (FC, Deplete)
15. Ribechini E, *et al.* 2009. *Eur. J. Immunol.* 39:3538.
16. Ng LG, *et al.* 2011. *J Invest. Dermatol.* 131:2058. [PubMed](#)
17. Ma C, *et al.* 2012. *J. Leukoc. Biol.* 92:1199.
18. McCartney-Francis, N, *et al.* 2014. *J Leukoc. Biol.* 96:917. [PubMed](#)
19. Her Z, *et al.* 2014. *EMBO Mol. Med.* 7:24. [PubMed](#)
20. Radtke AJ, *et al.* 2020. *Proc Natl Acad Sci U S A.* 117:33455-65. (SB) [PubMed](#)
21. Radtke AJ, *et al.* 2022. *Nat Protoc.* 17:378-401. (SB) [PubMed](#)

## Product Citations

1. Wong Fok Lung T, *et al.* 2020. *Nat Microbiol.* 141:5. [PubMed](#)
2. Gern BH, *et al.* 2021. *Cell Host Microbe.* 29(4):594-606.e6. [PubMed](#)
3. Cho SM *et al.* 2018. *Journal of neurochemistry.* 148(5):625-638. [PubMed](#)
4. Delvecchio FR, *et al.* 2021. *Cell Mol Gastroenterol Hepatol.* 12:1543. [PubMed](#)
5. Ercoli G, *et al.* 2021. *Front Immunol.* 11:611661. [PubMed](#)
6. Su N, Xiong Y 2016. *Sci Rep.* 6:22658. [PubMed](#)
7. Kwon O, *et al.* 2016. *Stem Cell Res.* 16: 682-691. [PubMed](#)
8. Kim AS, *et al.* 2021. *Cell.* 184(17):4414-4429.e19. [PubMed](#)
9. Maschmeyer P, *et al.* 2017. *J Autoimmun.* 10.1016/j.jaut.2017.11.005. [PubMed](#)
10. Misumi I *et al.* 2019. *Cell Rep.* 27(5):1387-1396. [PubMed](#)
11. Merz SF, *et al.* 2019. *Nat Commun.* 10:2312. [PubMed](#)
12. Rodriguez-Garcia A, *et al.* 2021. *Nat Commun.* 12:877. [PubMed](#)
13. Pan Y, *et al.* 2021. *Front Cell Neurosci.* 15:664312. [PubMed](#)
14. Plumlee CR, *et al.* 2020. *Cell Host Microbe.* 29(1):68-82.e5. [PubMed](#)
15. Liang W, *et al.* 2020. *Nat Commun.* 4.563888889. [PubMed](#)
16. Clement M, *et al.* 2016. *PLoS Pathog.* 12:e1006050. [PubMed](#)
17. Leech JM, *et al.* 2020. *Cell Host & Microbe.* 26(6):795-809.e5. [PubMed](#)
18. Haertel E, *et al.* 2018. *Eur J Immunol.* 48:1001. [PubMed](#)
19. Kwon O, *et al.* 2014. *Proc Natl Acad Sci U S A.* 111:592. [PubMed](#)
20. Liu Y, *et al.* 2015. *Sci Rep.* 5:17215. [PubMed](#)
21. Fuster JJ, *et al.* 2020. *Cell Rep.* 33:108326. [PubMed](#)
22. Uroda T, *et al.* 2020. *Nat Protoc.* 15:2107. [PubMed](#)
23. Park JA, *et al.* 2021. *J Hematol Oncol.* 14:142. [PubMed](#)
24. Mukherjee D, *et al.* 2022. *Nat Commun.* 13:3747. [PubMed](#)
25. Ostendorf BN, *et al.* 2020. *Nat Med.* 26:1048. [PubMed](#)
26. Lebratti T, *et al.* 2021. *eLife.* 10:00. [PubMed](#)
27. Bhattacharjee A, *et al.* 2019. *Commun Biol.* 2:450. [PubMed](#)
28. Privratsky JR, *et al.* 2018. *Am J Physiol Renal Physiol.* 315:F682. [PubMed](#)
29. Schlegel M, *et al.* 2018. *J Clin Invest.* 128:4711. [PubMed](#)
30. Francian A, *et al.* 2021. *J Drug Target.* 29:754. [PubMed](#)
31. Wang C, *et al.* 2021. *Cell Rep.* 37:110021. [PubMed](#)
32. McCullough LD, *et al.* 2021. *J Clin Invest.* 131:. [PubMed](#)
33. Sugita J, *et al.* 2021. *Nat Commun.* 12:1910. [PubMed](#)
34. Klopfenstein N, *et al.* 2021. *PLoS Pathog.* 17:e1009387. [PubMed](#)
35. Moses K, *et al.* 2016. *J Leukoc Biol.* 99: 811 - 823. [PubMed](#)
36. Zhang B, *et al.* 2016. *Mol Cell.* 63: 976-89. [PubMed](#)
37. Doty DT, *et al.* 2020. *Int J Mol Sci.* 21:00. [PubMed](#)
38. He W *et al.* 2018. *Immunity.* 49(6):1175-1190. [PubMed](#)
39. Dane EL, *et al.* 2022. *Nat Mater.* 21:710. [PubMed](#)
40. Kovacic B, *et al.* 2014. *Haematologica.* 99:1006. [PubMed](#)
41. Funk KE, *et al.* 2019. *J Neuroinflammation.* 16:22. [PubMed](#)
42. Tomlinson KL, *et al.* 2021. *Nat Commun.* 12:1399. [PubMed](#)
43. Riquelme SA, *et al.* 2020. *Cell Metabolism.* 31(6):1091-1106.e6. [PubMed](#)
44. Körner A, *et al.* 2019. *Nat Commun.* 10:633. [PubMed](#)
45. Hildebrand KM, *et al.* 2021. *PLoS One.* 16:e0253864. [PubMed](#)
46. Zhang T, *et al.* 2022. *Oncogene.* [PubMed](#)
47. Dang MT, *et al.* 2021. *Cell Reports.* 34(13):108917. [PubMed](#)
48. Körner A, *et al.* 2019. *Proc Natl Acad Sci U S A.* 116:20623. [PubMed](#)
49. Acker KP, *et al.* 2019. *iScience.* 19:281. [PubMed](#)
50. Niknam S, *et al.* 2018. *Clin Cancer Res.* 24:5735. [PubMed](#)
51. Cohen SB *et al.* 2018. *Cell host & microbe.* 24(3):439-446. [PubMed](#)
52. Zhang Y, *et al.* 2021. *J Immunol Res.* 2021:5599439. [PubMed](#)
53. Reinfeld BI, *et al.* 2021. *Nature.* 593:282. [PubMed](#)
54. Gurung P, *et al.* 2016. *Proc Natl Acad Sci U S A.* 113: 4452-4457. [PubMed](#)
55. Devaraj A, *et al.* 2021. *J Clin Invest.* 131:. [PubMed](#)
56. Maisel D, *et al.* 2016. *PLoS One.* 11: 0159716. [PubMed](#)
57. Ballet R, *et al.* 2014. *PLoS Pathog.* 10:1004550. [PubMed](#)
58. Puigdelloses M, *et al.* 2021. *J Immunother Cancer.* 9:. [PubMed](#)
59. Garcia-Bonilla L, *et al.* 2014. *J Immunol.* 193:2531. [PubMed](#)
60. Shepardson K, *et al.* 2016. *MBio.* 7: e00506-16. [PubMed](#)
61. Alam Z, *et al.* 2020. *Cell Rep.* 107825:31. [PubMed](#)
62. Mattila JT, *et al.* 2017. *J Immunol.* 199:806. [PubMed](#)
63. Blagih J, *et al.* 2020. *Cell Rep.* 30:481. [PubMed](#)

64. Klein JC, *et al.* 2017. Nat Commun. 8:14600. [PubMed](#)
65. Dang MT, *et al.* 2021. STAR Protoc. 2:100957. [PubMed](#)
66. Li D, *et al.* 2022. Emerg Microbes Infect. 11:2248. [PubMed](#)
67. Desai P, *et al.* 2021. Cell. 184(5):1214-1231.e16. [PubMed](#)
68. Xu G, *et al.* 2020. Cell Rep. 32:108170. [PubMed](#)
69. Chen Z, *et al.* 2016. Nat Commun. 7:11596. [PubMed](#)
70. Lokken K, *et al.* 2014. PLoS Pathog. 10:1004049. [PubMed](#)
71. Muri J, *et al.* 2020. eLife. 9:e53627. [PubMed](#)
72. Sun X, *et al.* 2020. Cell Metabolism. 31(1):189-206.e8. [PubMed](#)
73. Yeung F, *et al.* 2020. Cell Host & Microbe. 27(5):809-822. [PubMed](#)
74. Xueyang Yu *et al.* 2017. Immunity. 47(5):903-912. [PubMed](#)
75. Chan WY, *et al.* 2019. Infect Immun. 87. [PubMed](#)
76. Kobia FM, *et al.* 2020. PLoS Biol. 18:e3000850. [PubMed](#)
77. Karki R, *et al.* 2020. bioRxiv. [PubMed](#)
78. Bennett FC, *et al.* 2018. Neuron. 98:1170. [PubMed](#)
79. Karki R, *et al.* 2021. Cell. 184:149. [PubMed](#)
80. Jablonski K, *et al.* 2015. PLoS One. 10: 0145342. [PubMed](#)
81. Salazar V, *et al.* 2019. Cell Rep. 26:1585. [PubMed](#)
82. Dymek B, *et al.* 2022. J Inflamm Res. 15:5621. [PubMed](#)
83. Milich LM, *et al.* 2021. J Exp Med. 218. [PubMed](#)
84. Kiss M, *et al.* 2020. Cancer Immunol Res. 9:309. [PubMed](#)
85. Dai X, *et al.* 2021. Molecular Cell. 81(11):2317-2331.e6. [PubMed](#)
86. Roediger B *et al.* 2018. Cell. 175(2):530-543. [PubMed](#)
87. Ireland L, *et al.* 2020. Front Immunol. 11:297. [PubMed](#)
88. Fedele C, *et al.* 2021. J Exp Med. 218. [PubMed](#)
89. Deliyannis G, *et al.* 2021. JCI Insight. 6. [PubMed](#)
90. Nakayama Y, *et al.* 2020. Proc Natl Acad Sci U S A. 117:14365. [PubMed](#)
91. Garcia-Bonilla L, *et al.* 2015. J Neurosci. 35: 14783 - 14793. [PubMed](#)
92. Seenappa LM, *et al.* 2022. NPJ Vaccines. 7:128. [PubMed](#)
93. Verma M, *et al.* 2021. J Exp Med. 218. [PubMed](#)
94. Zhu Y *et al.* 2017. The Journal of Neuroscience. 37(9):2362-2376. [PubMed](#)
95. Trivedi S, *et al.* 2020. Elife. 9:00. [PubMed](#)
96. Amber Smith, Amanda Smith 2016. Sci Rep. 6:38703. [PubMed](#)
97. Kim I *et al.* 2015. Brain and behavior. 5(12):e00403. [PubMed](#)
98. Syed I *et al.* 2018. Cell metabolism. 27(2):419-427. [PubMed](#)
99. Hohsfield LA, *et al.* 2021. Elife. 10. [PubMed](#)
100. Yang F, *et al.* 2021. Nat Commun. 12:3424. [PubMed](#)

**RRID** AB\_1877272 (BioLegend Cat. No. 127615)  
 AB\_1877271 (BioLegend Cat. No. 127616)

## Antigen Details

---

<b>Structure</b>	A 21-35 kD GPI-anchored membrane protein
<b>Distribution</b>	Expressed on the majority of myeloid cells in bone marrow and peripheral granulocytes. The monoclonal antibody RB6-8C5 recognizes both Ly-6G and Ly-6C.
<b>Cell Type</b>	Granulocytes, Macrophages, Monocytes
<b>Biology Area</b>	Immunology, Innate Immunity
<b>Antigen References</b>	Fleming TJ, <i>et al.</i> 1993. <i>J. Immunol.</i> 151:2399.
<b>Gene ID</b>	<a href="#">546644</a>

## Related Protocols

---

[Cell Surface Flow Cytometry Staining Protocol](#)

## Other Formats


---

Alexa Fluor® 594 anti-mouse Ly-6G, Purified anti-mouse Ly-6G, Biotin anti-mouse Ly-6G, FITC anti-mouse Ly-6G, PE anti-mouse Ly-6G, Alexa Fluor® 647 anti-mouse Ly-6G, Pacific Blue™ anti-mouse Ly-6G, APC anti-mouse Ly-6G, PerCP/Cyanine5.5 anti-mouse Ly-6G, PE/Cyanine7 anti-mouse Ly-6G, Alexa Fluor® 700 anti-mouse Ly-6G, APC/Cyanine7 anti-mouse Ly-6G, Alexa Fluor® 488 anti-mouse Ly-6G, Brilliant Violet 421™ anti-mouse Ly-6G, Brilliant Violet 570™ anti-mouse Ly-6G, Ultra-LEAF™ Purified anti-mouse Ly-6G, Brilliant Violet 510™ anti-mouse Ly-6G, Purified anti-mouse Ly-6G (Maxpar® Ready), Brilliant Violet 650™ anti-mouse Ly-6G, Brilliant Violet 711™ anti-mouse Ly-6G, Brilliant Violet 605™ anti-mouse Ly-6G, Brilliant Violet 785™ anti-mouse Ly-

6G, PE/Dazzle™ 594 anti-mouse Ly-6G, APC/Fire™ 750 anti-mouse Ly-6G, PerCP anti-mouse Ly-6G, TotalSeq™-A0015 anti-mouse Ly-6G, TotalSeq™-C0015 anti-mouse Ly-6G, TotalSeq™-B0015 anti-mouse Ly-6G, Spark Blue™ 550 anti-mouse Ly-6G, Spark NIR™ 685 anti-mouse Ly-6G, Spark YG™ 593 anti-mouse Ly-6G, APC/Fire™ 810 anti-mouse Ly-6G Antibody, PE/Cyanine5 anti-mouse Ly-6G, PE/Fire™ 810 anti-mouse Ly-6G Antibody, Spark UV™ 387 anti-mouse Ly-6G, PE/Fire™ 640 anti-mouse Ly-6G

## Product Data

---



C57BL/6 bone marrow cells stained with  
1A8 PerCP/Cyanine5.5

For research use only. Not for diagnostic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products.

\*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, [www.biolegend.com/ordering#license](http://www.biolegend.com/ordering#license)). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products, reverse engineer functionally similar materials, or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

BioLegend Inc., 8999 BioLegend Way, San Diego, CA 92121 [www.biolegend.com](http://www.biolegend.com)  
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587